Meta‐analysis of health‐related quality of life after minimally invasive versus open oesophagectomy for oesophageal cancer. BJS 2017; 104: 1131-1140.
Published: 20th June 2017
Authors: J. H. Kauppila, S. Xie, A. Johar, S. R. Markar, P. Lagergren
The aim of this systematic review and meta‐analysis was to compare health‐related quality of life (HRQoL) outcomes between minimally invasive and open oesophagectomy for cancer at different postoperative time points.
A search of PubMed (MEDLINE), Web of Science, Embase, Scopus, CINAHL and the Cochrane Library was performed for studies that compared open with minimally invasive oesophagectomy. A random‐effects meta‐analysis was conducted for studies that measured HRQoL scores using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ‐C30 and QLQ‐OES18 questionnaires. Mean differences (MDs) greater than 10 in scores were considered clinically relevant. Pooled effects of MDs with 95 per cent confidence intervals were estimated to assess statistical significance.
Nine studies were included in the qualitative analysis, involving 1157 patients who had minimally invasive surgery and 907 patients who underwent open surgery. Minimally invasive surgery resulted in better scores for global quality of life (MD 11·61, 95 per cent c.i. 3·84 to 19·39), physical function (MD 11·88, 3·92 to 19·84), fatigue (MD −13·18, −17·59 to −8·76) and pain (MD −15·85, −20·45 to −11·24) compared with open surgery at 3 months after surgery. At 6 and 12 months, no significant differences remained.
Patients report better global quality of life, physical function, fatigue and pain 3 months after minimally invasive surgery compared with open surgery. No such differences remain at longer follow‐up of 6 and 12 months.Read more
You may also be interested in
Effect of age on rates of palliative surgery and chemotherapy use in patients with locally advanced or metastatic gastric cancer.
Authors: S. D. Nelen, M. van Putten, V. E. P. P. Lemmens, K. Bosscha, J. H. W. de Wilt, R. H. A. Verhoeven et al.
Notes: Less surgery, more chemo, but no change in survival
Changes in treatment and outcome of oesophageal cancer in Denmark between 2004 and 2013. BJS 2017; 104: 1338-1345.
Authors: D. W. Kjaer, H. Larsson, L. B. Svendsen, L. S. Jensen
Notes: Better short‐term outcome
Randomized clinical trial
Randomized clinical trial of psychological support and sleep adjuvant measures for postoperative sleep disturbance in patients undergoing oesophagectomy. BJS 2017; 104: 1307-1314.
Authors: M. Scarpa, E. Pinto, E. Saraceni, F. Cavallin, M. Parotto, R. Alfieri et al.
Notes: Psychologists improve postoperative sleep
Adaptation of the By‐Band randomized clinical trial to By‐Band‐Sleeve to include a new intervention and maintain relevance of the study to practice. BJS 2017; 104: 1207-1214.
Authors: C. A. Rogers, B. C. Reeves, J. Byrne, J. L. Donovan, G. Mazza, S. Paramasivan et al.
Notes: Something to consider
Loss of SRY‐box2 (SOX2) expression and its impact on survival of patients with oesophageal adenocarcinoma. BJS 2017; 104: 1327-1337.
Authors: F. J. C. ten Kate, S. H. van Olphen, M. J. Bruno, B. P. L. Wijnhoven, J. J. B. van Lanschot, L. H. J. Looijenga et al.
Notes: Useful biomarker, especially for early disease
Authors: J. Thereaux, T. Lesuffleur, M. Païta, S. Czernichow, A. Basdevant, S. Msika et al.
Notes: Poor follow‐up despite international guidelines
Authors: C. Lin, H. Liu, H. Zhang, Y. Cao, R. Li, S. Wu et al.
Notes: Tumour microenvironment is important
Corrigendum: Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer. BJS 2017; 104: 947-947.
Authors: J. M. Findlay, K. M. Bradley, L. M. Wang, J. M. Franklin, E. J. Teoh, F. V. Gleeson et al.
Preoperative imaging and prediction of oesophageal conduit necrosis after oesophagectomy for cancer. BJS 2017; 104: 1346-1354.
Authors: P. Lainas, D. Fuks, S. Gaujoux, Z. Machroub, A. Fregeville, T. Perniceni et al.
Notes: Vascular abnormalities may be causal
Validation of two prognostic models for recurrence and survival after radical gastrectomy for gastric cancer. BJS 2017; 104: 1235-1243.
Authors: M. Bencivenga, G. Verlato, D.‐S. Han, D. Marrelli, F. Roviello, H.‐K. Yang et al.
Notes: Good performance
Survival benefit of liver resection for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma. BJS 2017; 104: 1045-1052.
Authors: H. Kim, S. W. Ahn, S. K. Hong, K. C. Yoon, H.‐S. Kim, Y. R. Choi et al.
Notes: Selected patients benefit
Validation of a nomogram for selecting patients for chemotherapy after D2 gastrectomy for cancer. BJS 2017; 104: 1226-1234.
Authors: Z.‐X. Wang, G.‐X. Li, Z.‐W. Zhou, Z.‐P. Huang, F. Wang, R.‐H. Xu et al.
Notes: Facilitates individualized treatment